Cardiac Amyloidosis and the V142I Transthyretin Variant
Listen now
Description
What is the natural history and cardiovascular burden of the V142I transthyretin variant among US Black individuals who carry this variant? Senthil Selvaraj, MD, MS, MA, from Duke University, and Scott D. Solomon, MD, from Brigham and Women’s Hospital, discuss this and more with JAMA Executive Editor Gregory Curfman, MD.
Related Content:
Cardiovascular Burden of the V142I Transthyretin Variant Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger Heart Failure in African American Individuals, Version 2.0 Cardiac Amyloidosis Due to Transthyretin Protein
More Episodes
Joel M. Dulhunty, MD, PhD, Royal Brisbane and Women’s Hospital, and Jason A. Roberts, BPharm, PhD, University of Queensland Centre for Clinical Research, join JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss the BLING trial that assessed continuous vs intermittent β-lactam antibiotic...
Published 06/12/24
Forced nitrogen inhalation was used by the state of Alabama to execute Kenneth Smith on January 25, 2024. Some politicians, attorneys general, and health care practitioners support its use for capital punishment in the US. Philip E. Bickler, MD, PhD, and Michael S. Lipnick, MD, discuss the...
Published 05/29/24
Guidelines call for better evidence on the health outcomes after living kidney donation. Author Amit X. Garg, MD, PhD, London Health Sciences Centre, and editorialist Elizabeth C. Lorenz, MD, Baylor College of Medicine, discuss a new study that compares the risks of hypertension and other health...
Published 05/23/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
